Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) CEO Daniel Barber sold 8,257 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $4.29, for a total transaction of $35,422.53. Following the transaction, the chief executive officer directly owned 660,574 shares of the company’s stock, valued at $2,833,862.46. This represents a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Barber also recently made the following trade(s):
- On Tuesday, March 10th, Daniel Barber sold 180,677 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $4.17, for a total transaction of $753,423.09.
Aquestive Therapeutics Stock Down 1.1%
Shares of NASDAQ:AQST traded down $0.05 during trading on Monday, hitting $4.13. 2,112,071 shares of the stock traded hands, compared to its average volume of 3,590,827. The company has a market cap of $517.48 million, a price-to-earnings ratio of -6.76 and a beta of 1.50. The company has a fifty day moving average price of $4.16 and a two-hundred day moving average price of $4.76. Aquestive Therapeutics, Inc. has a 52-week low of $2.22 and a 52-week high of $7.55.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on AQST shares. Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Monday, April 20th. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Oppenheimer started coverage on shares of Aquestive Therapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $8.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $8.80.
View Our Latest Report on Aquestive Therapeutics
Institutional Investors Weigh In On Aquestive Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aberdeen Group plc acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $3,494,000. Blue Owl Capital Holdings LP boosted its holdings in shares of Aquestive Therapeutics by 35.9% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 1,250,000 shares of the company’s stock worth $6,988,000 after purchasing an additional 330,000 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $4,381,000. Oppenheimer & Co. Inc. acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $187,000. Finally, MONECO Advisors LLC boosted its holdings in shares of Aquestive Therapeutics by 106.2% during the 3rd quarter. MONECO Advisors LLC now owns 37,865 shares of the company’s stock worth $212,000 after purchasing an additional 19,500 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
Recommended Stories
- Five stocks we like better than Aquestive Therapeutics
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
